← All Insmed INC filings

Insmed INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
INSM
Insmed INC
SCHEDULE: FMR LLC Reports 7.4% Stake in Insmed Inc.
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 16,127,583 shares, representing 7.4% of Insmed Inc.'s common stock as of June 30, 2026.
NASDAQ
INSM
Insmed INC
SCHEDULE: JPMorgan Chase Discloses Insmed Stake
JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Insmed Incorporated's common stock as of June 30, 2026.
NASDAQ
INSM
Insmed INC
SCHEDULE: Darwin Global Discloses 7.8% Stake in Insmed
Darwin Global Management and Dr. Abhishek Trehan have reported a 7.8% beneficial ownership stake in Insmed Incorporated.
NASDAQ
INSM
Insmed INC
SCHEDULE: FMR LLC Discloses 6.1% Stake in Insmed Inc.
FMR LLC, through its subsidiaries and affiliates, has reported beneficial ownership of 13,145,166.52 shares, representing 6.1% of the outstanding common stock of Insmed Inc. as of March 31, 2026.
NASDAQ
INSM
Insmed INC
SCHEDULE: Vanguard Group Reduces Insmed Stake to Zero
The Vanguard Group reported a 0% beneficial ownership in Insmed Inc. common stock following an internal realignment.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: BlackRock Reports 6.6% Stake in INSMED INC
BlackRock, Inc. has disclosed a 6.6% beneficial ownership stake in INSMED INC's common stock as of December 31, 2025.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: Darwin Global Boosts Insmed Stake to 9.7%
Darwin Global Management, Ltd. and its affiliates reported an increased beneficial ownership of 9.7% in Insmed Inc., holding 20,457,445 shares of common stock.
NASDAQ
INSM
Insmed INC
SCHEDULE: T. Rowe Price Cuts INSMED Stake Below 5%
T. Rowe Price Associates, Inc. has reduced its beneficial ownership in INSMED INC to 3.3% as reported in its latest Schedule 13G amendment.
NASDAQ
INSM
Insmed INC
SCHEDULE: JPMorgan Chase Discloses 10.8% Stake in INSMED INC.
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 10.8% beneficial ownership stake in INSMED INCORPORATED.
NASDAQ
INSM
Insmed INC
SCHEDULE: T. Rowe Price Boosts INSMED Stake to 5.9%
T. Rowe Price Associates, Inc. reported an aggregate beneficial ownership of 5.9% of INSMED INC's common stock as of June 30, 2025.
NASDAQ
INSM
Insmed INC
SCHEDULE: JPMorgan Chase & Co. Discloses 7.9% Stake in Insmed Incorporated
JPMorgan Chase & Co. has disclosed a 7.9% beneficial ownership stake in Insmed Incorporated, holding over 15 million shares as of June 30, 2025.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: BlackRock Discloses 5.1% Stake in INSMED INC
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in INSMED INC as of June 30, 2025, primarily for investment purposes.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: Darwin Global Management and Affiliates Disclose 8.5% Passive Stake in INSMED Inc.
Darwin Global Management, Ltd., Dr. Abhishek Trehan, and Darwin Global Master Fund, Ltd. have collectively reported a passive beneficial ownership of 8.5% of INSMED Inc.'s common stock as of March 31, 2025.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: Darwin Global Management Discloses Significant 7.2% Stake in INSMED Inc.
Darwin Global Management, along with its affiliates, has disclosed a beneficial ownership of 7.2% in INSMED Inc.'s common stock, totaling 12,960,538 shares.
NASDAQ
INSM
Insmed INC
SCHEDULE 13G/A: Vanguard Group Amends Stake in Insmed Inc, Reports Over 10% Beneficial Ownership
The Vanguard Group has filed an amended Schedule 13G, disclosing a 10.18% beneficial ownership stake in Insmed Inc as of December 31, 2024.